List of Excipients in Branded Drug PROVIGIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	LACTOSE
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	MAGNESIUM STEARATE
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	POVIDONE
Rebel Distributors Corp	PROVIGIL	modafinil	21695-235	STARCH, CORN

PROVIGIL Excipient Strategy and Commercial Opportunities for Modafinil

Last updated: August 13, 2026

Provigil is the branded immediate-release modafinil tablet originally developed by Cephalon and now associated with Teva Pharmaceuticals. Its core composition is conventional: lactose-based diluent, starch, croscarmellose sodium, povidone, magnesium stearate and film-coating materials. The commercial opportunity is no longer protection of the original tablet. It is differentiated delivery, patient-specific formulations, manufacturing efficiency and regulatory positioning around modafinil products that improve convenience, tolerability or adherence.

The U.S. market has no meaningful branded exclusivity barrier comparable to the product’s original launch period. Modafinil generics have been marketed for years, and the original Provigil patent estate has largely expired. New products would need to compete on formulation performance, dosage form, supply reliability, pricing or a clinically differentiated route of administration.

What is Provigil and what excipients does the product contain?

Provigil is an immediate-release oral tablet containing modafinil in 100 mg and 200 mg strengths. The FDA-approved indications are narcolepsy, obstructive sleep apnea-associated excessive sleepiness and shift work sleep disorder [1].

The approved Provigil labeling identifies inactive ingredients that include lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate and tablet-coating components. The exact composition and colorant system can vary by strength and manufacturing presentation. The FDA label should control any final formulation comparison because excipient specifications and coating compositions can change over a product’s commercial history [1].

Product attribute	Provigil position
Active ingredient	Modafinil
Dosage form	Immediate-release film-coated tablet
Strengths	100 mg and 200 mg
Original U.S. NDA	NDA 020717
Initial FDA approval	1998
Approved uses	Narcolepsy, obstructive sleep apnea-associated sleepiness, shift work sleep disorder
Original developer	Cephalon
Current commercial affiliation	Teva Pharmaceuticals following acquisition of Cephalon
U.S. generic status	Multiple generic modafinil products
Biosimilar relevance	None; modafinil is a small molecule

The excipient system supports conventional wet or dry granulation and direct-compression development, depending on the manufacturer’s process. Lactose and starch provide bulk and compactibility. Croscarmellose sodium supports rapid tablet disintegration. Povidone can function as a binder, while magnesium stearate controls ejection and die-wall friction. The formulation is not technically difficult to reproduce, but bioequivalence performance depends on particle size, granulation endpoint, compression force, lubricant exposure and dissolution control.

What excipient strategy is appropriate for a modafinil generic?

The lowest-risk approach is an immediate-release tablet that matches the reference product’s dissolution profile and uses well-established pharmaceutical excipients. A generic manufacturer should prioritize process robustness over unnecessary composition changes.

Conventional immediate-release tablet

A conventional formulation can use:

• Lactose monohydrate or microcrystalline cellulose as diluent
• Pregelatinized starch or povidone as binder
• Croscarmellose sodium or sodium starch glycolate as disintegrant
• Colloidal silicon dioxide as glidant
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Hypromellose-based film coating

The main development risks are not novelty but performance. Excessive magnesium stearate can slow wetting and dissolution. High compression force can reduce tablet porosity and delay disintegration. Povidone level and granulation moisture can affect hardness, friability and release. Modafinil particle size and polymorphic form also require control because they can influence dissolution and content uniformity.

Lactose-free and low-allergen positioning

A lactose-free formulation could target patients with lactose intolerance, healthcare systems that prefer excipient simplification and international markets with different excipient restrictions. Microcrystalline cellulose, mannitol, dibasic calcium phosphate or partially pregelatinized starch could replace lactose.

This strategy has commercial value only if the product can demonstrate equivalent bioavailability and stable tablet performance. Lactose removal alone is unlikely to create durable patent protection. It may, however, support a differentiated label, procurement specification or line extension.

Low-moisture and direct-compression manufacturing

A direct-compression formulation could reduce processing time, water exposure and manufacturing complexity. The development challenge is achieving uniform distribution of modafinil at scale while maintaining acceptable tablet tensile strength and rapid disintegration.

For a high-volume generic, a robust excipient platform can reduce batch failure risk and improve cost of goods. Mannitol and microcrystalline cellulose can support a low-moisture process, while co-processed excipients may improve flow and compaction. These products may be protectable through formulation or manufacturing patents, but broad claims are vulnerable if the excipient combination is routine and the performance improvement is not unexpected.

What formulations are protected or commercially attractive beyond Provigil?

The strongest commercial opportunities are dosage forms that solve a clear use problem. Modafinil is already available as a low-cost oral tablet, so a new product must provide more than a different filler or coating.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients who have difficulty swallowing or who need medication without water. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose and flavoring systems are common development tools.

The main technical barriers include:

• Bitter or lingering taste
• Tablet friability
• Moisture sensitivity
• Dose loading at 200 mg
• Rapid disintegration without excessive dusting
• Preservation of dissolution and bioequivalence

Taste masking is commercially relevant because modafinil’s dose is relatively high for an orally disintegrating product. Polymer coating, ion-exchange resins, lipid-based barriers and multiparticulate technology could be used, but each adds manufacturing cost and may complicate regulatory comparability.

Oral suspension or liquid formulation

A liquid product could target pediatric or geriatric patients, although the approved Provigil indications and population are not equivalent to a general pediatric sleepiness market. A liquid formulation would require attention to sedimentation, chemical stability, microbial control, preservative exposure and dosing-device accuracy.

A suspension is more plausible than a true solution because modafinil has limited aqueous solubility. Surfactants, wetting agents, suspending polymers and particle-size reduction can improve performance. A 505(b)(2) pathway could be relevant if the sponsor seeks a new dosage form or a labeling change supported by the reference product, but development would require an FDA-supported clinical and pharmacokinetic strategy.

Sprinkle capsules and multiparticulates

A capsule containing coated pellets could permit administration to patients unable to swallow tablets. Multiparticulates can also support taste masking and flexible dosing. The tradeoff is a higher cost structure and greater risk of dose segregation, capsule-content variability and coating defects.

This platform may be attractive for specialty channels, but it is unlikely to compete effectively against commodity generic tablets without reimbursement or adherence advantages.

Modified-release formulations

A modified-release product could seek to reduce peak-related adverse effects, extend wakefulness coverage or provide once-daily exposure with a different pharmacokinetic profile. The opportunity is technically substantial but regulatory risk is high.

Modafinil’s approved clinical use already relies on once-daily or scheduled dosing in many patients. A modified-release product would need to demonstrate a clinically meaningful benefit, not merely a different dissolution curve. Formulation patents could cover matrix composition, multiparticulate release coatings, osmotic systems or pharmacokinetic parameters. Such claims are vulnerable if the product does not establish improved safety, adherence or clinical control.

How strong is the Provigil patent estate?

The original U.S. patent estate has limited current blocking value because the principal composition and early formulation protections expired years ago.

Patent category	Historical relevance	Current commercial effect
Modafinil composition patents	Protected the original active ingredient and early commercialization	Expired
Polymorph and solid-state patents	Addressed crystalline form and manufacturing control	Historical significance; assess jurisdiction-specific status
Immediate-release formulation patents	Supported tablet composition and release characteristics	Generally expired or no longer blocking U.S. generic entry
Method-of-use patents	Covered narcolepsy, sleep apnea and shift-work-related sleepiness concepts	Scope and enforceability depended on claim language and listing status
Manufacturing patents	Could address particle size, crystallization or process conditions	May still matter in selected jurisdictions or for confidential know-how
New delivery-system patents	Potentially relevant to future ODT, liquid or modified-release products	Available to new entrants if claims are technically differentiated

Patent strength should be analyzed claim by claim. A patent directed to a specific polymorph, particle-size distribution, excipient ratio or dissolution profile may create a narrower manufacturing barrier than a broad formulation patent. Trade secrets can be more important than patents for crystallization conditions, milling parameters, granulation endpoints and coating processes.

When did Provigil lose exclusivity and when can generics enter?

Provigil lost practical U.S. market exclusivity after generic modafinil approvals and commercial entry. Cephalon entered settlement arrangements with generic manufacturers that delayed certain launches relative to the earliest possible patent challenges. Generic modafinil products subsequently entered the U.S. market, and the product is now a mature generic category.

The key milestones were:

Event	Approximate timing
Provigil FDA approval	1998
Early composition patent protection	Expired in the early 2000s, subject to patent-term and pediatric adjustments
Generic patent challenges and litigation	Primarily 2000s to early 2010s
Major generic entry period	2012 and after
Current U.S. market position	Mature generic market

FDA Orange Book analysis should distinguish patents historically listed for NDA 020717 from patents currently relevant to an ANDA. A patent may remain visible in historical litigation records while no longer blocking approval. The Orange Book also does not capture every possible process, manufacturing or international patent right [2].

What Paragraph IV challenges and litigation affected Provigil?

Provigil was the subject of extensive generic litigation involving Cephalon and several ANDA applicants. The disputes centered on modafinil patents, including patents associated with the product’s composition, crystalline form and formulation.

The most commercially important issue was the timing of generic entry. Cephalon reached settlements with generic applicants, including arrangements involving Teva, Ranbaxy, Mylan and other companies. The Federal Trade Commission later challenged certain reverse-payment settlement practices in the pharmaceutical industry, and the Supreme Court addressed the legal framework for evaluating such settlements in FTC v. Actavis, Inc. [3].

The litigation produced two business conclusions:

1. The principal barrier was entry timing, not a permanently durable formulation moat.
2. Settlement economics materially influenced the period during which Provigil retained branded sales protection.

A current generic entrant should evaluate remaining litigation risk through live Orange Book listings, FDA patent certifications, active district-court cases and any patent covering a specific new formulation. Historical Provigil litigation alone does not establish a current infringement barrier.

What is the FDA and Orange Book status of Provigil?

Provigil was approved under NDA 020717 as an oral tablet. Modafinil generics are approved through ANDAs referencing the Provigil product. FDA approval of an ANDA depends on pharmaceutical equivalence, bioequivalence, manufacturing quality and applicable patent certifications or exclusivity requirements [2].

Provigil is not a biologic, so biosimilar regulation does not apply. The relevant regulatory routes are:

• ANDA for an equivalent immediate-release tablet
• 505(b)(2) NDA for a materially different dosage form or formulation
• Full NDA if the sponsor cannot rely adequately on existing safety and efficacy findings

A new ODT, liquid, sprinkle product or modified-release formulation may require more than a standard ANDA, particularly if the dosage form changes pharmacokinetic exposure or requires new clinical evidence.

Which companies compete with Provigil and modafinil generics?

The competitive field includes Teva’s branded and generic interests, established generic manufacturers and specialty pharmaceutical companies developing wakefulness products.

The main competitive categories are:

Category	Competitive basis
Generic modafinil tablets	Lowest acquisition cost and broad distribution
Armodafinil products	Longer-acting enantiomer-related positioning and differentiated prescribing
Solriamfetol	Alternative wakefulness therapy with a separate mechanism and newer commercial positioning
Pitolisant	Non-stimulant wake-promoting option with different pharmacology
Specialty formulations	Convenience, adherence, swallowing support or controlled release
Compounded products	Limited, variable and generally weaker as a branded commercial competitor

Modafinil’s low generic price creates a high hurdle for a new formulation. A differentiated product would need to show improved persistence, better tolerability, easier administration or a clearly defined specialty population.

What commercial opportunities exist for a new modafinil excipient platform?

The most credible opportunities are narrow and product-specific.

Generic cost leadership

A manufacturer can use a simple, scalable formulation to compete through manufacturing cost, supply reliability and multisource procurement. The value lies in process control rather than strong intellectual property.

Patient-centric dosage forms

ODT, sprinkle and liquid products can target patients with dysphagia, variable administration conditions or adherence problems. These products are more likely to support premium pricing than a lactose-free conventional tablet.

International product adaptation

Excipient restrictions, labeling requirements and procurement preferences differ across jurisdictions. A platform using broadly accepted excipients can simplify global registration. Geographic patents may remain relevant for novel delivery systems even when the original U.S. Provigil patents have expired.

Manufacturing know-how

Crystallization, particle engineering, milling, granulation and coating processes can create practical barriers. These protections may be maintained as trade secrets where patent disclosure would provide competitors with a usable process blueprint.

What generic launch risks exist for Provigil or modafinil?

The principal risks are commercial and regulatory:

• Low generic pricing limits return on formulation investment.
• A new dosage form may require a 505(b)(2) program rather than an ANDA.
• Modafinil’s dose may make ODT and liquid presentations difficult to commercialize.
• Formulation changes can alter dissolution and pharmacokinetic exposure.
• Taste masking can increase cost and manufacturing complexity.
• Existing generic supply may make payer adoption difficult.
• Method-of-use claims must be reviewed for infringement and labeling risk.
• Manufacturing patents may differ by country even after U.S. composition patents expire.
• The wakefulness market includes newer alternatives with different mechanisms and clinical positioning.

Key Takeaways

• Provigil is an immediate-release modafinil tablet with a conventional excipient system.
• The original U.S. patent estate no longer provides a substantial branded barrier to standard generic entry.
• The most viable excipient strategies are robust immediate-release tablets, lactose-free products, ODTs, sprinkle capsules and carefully justified liquid formulations.
• Excipient substitution alone is unlikely to support durable patent protection.
• New commercial value must come from administration, adherence, tolerability, manufacturing efficiency or specialty-market positioning.
• A conventional generic generally fits the ANDA pathway; materially different dosage forms may require a 505(b)(2) NDA.
• Provigil has no biosimilar issue because modafinil is a small-molecule drug.
• Historical Paragraph IV litigation and settlement agreements affected launch timing but should not be treated as current blocking rights without a live patent review.
• The strongest practical barriers for future products may be process know-how, taste-masking technology and clinically meaningful delivery performance.

FAQs

Can a lactose-free modafinil tablet receive separate patent protection?

Yes, but lactose removal alone is unlikely to support a strong patent. Protection would require a novel formulation, unexpected performance, a specific excipient relationship or a manufacturing advantage that satisfies patentability standards.

Is modafinil suitable for an orally disintegrating tablet?

Yes, but the 100 mg and 200 mg doses create dose-loading and taste-masking challenges. Mannitol, superdisintegrants, coated particles and flavor systems are possible development tools.

Does Provigil have biosimilar competition?

No. Modafinil is a chemically synthesized small molecule. Competition occurs through ANDA-approved generics and alternative small-molecule wakefulness drugs.

Can a new liquid modafinil product rely on the Provigil approval?

Potentially, but a liquid formulation may require a 505(b)(2) NDA rather than an ANDA. The regulatory pathway depends on formulation differences, pharmacokinetic comparability, proposed labeling and the sponsor’s reliance strategy.

What is the highest-value excipient opportunity for modafinil?

A patient-centric dosage form with a defined clinical or adherence advantage has greater value than a routine excipient substitution. ODT, sprinkle and liquid products are the most plausible candidates, but each requires evidence that the benefit supports premium pricing.

References

1. U.S. Food and Drug Administration. (2015). Provigil (modafinil) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).